Global Somatostatin Receptor Type 2 Market is segmented By Type (CRN-00808, Lanreotide Acetate, PRL-2903, Others), By Application (Hormonal Disorder, Oncology, Metabolic Disorder), By Region (North America, Europe, South America, Asia-Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Somatostatin Receptor Type 2 Market Overview
The Global Somatostatin Receptor Type 2 Market is predicted to reach at a high CAGR during the forecast period (2023-2030). The patients with neuroendocrine tumors that over-express the somatostatin receptor 2 have an improved prognosis. The overexpression of SSTR2 in tumors can be exploited to deliver radio-peptides to tumors to detect or destroy them selectively. North America dominated the market. Competitive rivalry intensifies with Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd and others operating in the market.
Somatostatin Receptor Type 2 Market Summary
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other vital insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Download Sample
Somatostatin Receptor Type 2 Market Dynamics
The increasing prevalence of acromegaly is expected to drive the growth of the market.
According to the National Organization for Rare Disorders, Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. It befalls when the pituitary gland produces too much growth hormone (GH). These hormones control many different bodily functions. In most patients, acromegaly is produced by the growth of a benign tumor (adenoma) arising from the pituitary gland. Moreover, symptoms of acromegaly involve abnormal enlargement in bones of the hands, arms, feet, legs and head. Enlargement of the bones in the jaws and the front of the skull is typically the most likely bony change.
Additionally, that affects males and females in even numbers. This disorder occurs in approximately 50 to 70 people per million. Researchers expect that three to eleven people out of every million develop the disorder each year. However, because the symptoms of acromegaly may develop slowly, the disorder may often remain unrecognized. Therefore, it may be underdiagnosed, making it difficult to determine the true frequency of acromegaly in the general population.
Acromegaly can occur at any age after puberty but most often occurs during the fourth and fifth decades. When the excessive secretion of growth hormone occurs before puberty, the disorder is known as gigantism, not acromegaly. Thus, from the above statements, the market is expected to drive in the forecast period.
Detection of blood-brain barrier permeability using GPCR internalization is expected to drive the growth of the somatostatin receptor type 2 market.
According to the article, 8 September 2020. Impairment of the blood-brain barrier (BBB) is involved in numerous neurological diseases from developmental to aging stages. Reliable imaging of increased BBB permeability is therefore crucial for basic research and preclinical studies. Today, the analysis of extravasation of exogenous dyes is the principal method to study BBB leakage. However, these procedures are challenging to apply in pups and embryos and may appear difficult to interpret. They have introduced a novel approach based on agonist-induced internalization of a neuronal G protein-coupled receptor widely distributed in the mammalian brain, the somatostatin receptor type 2 (SST2).
Moreover, the clinically approved SST2 agonist octreotide (1 kDa), when injected intraperitoneally, does not cross an intact BBB. However, at sites of BBB permeability, OCT extravasates and induces SST2 internalization from the neuronal membrane into perinuclear compartments. It allows an unambiguous localization of increased BBB permeability by classical immunohistochemical procedures using specific antibodies against the receptor. Therefore, this approach provides an alternative and simple way to assess BBB dysfunction and development in different physiological and pathological conditions expected to drive the market in the forecast period.
Side effects of the treatment of acromegaly are expected to hamper the growth of the market.
According to the article(Frontiers), on March 15, 2021. The side effects of treatment, acromegaly patients often still experience disease symptoms even when therapy successfully controls GH and IGF-1 levels. Symptoms and side effects can negatively impact patients’ health-related quality of life. This study examines the disease- and treatment-related burden associated with SRL injections as reported using the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ ©) and clinician-reported symptom severity through the Acromegaly Index of Severity (AIS).
Two-thirds of patients reported that they still experience acromegaly symptoms; 82% of these said they experience symptoms all of the time. Three-fourths experienced gastrointestinal (GI) side effects after injections, and 77% experienced treatment-related injection site reactions (ISRs). Patients commonly reported that these interfered with their daily life, leisure, and work activities. This study highlights the significant disease burden that persists for patients with acromegaly that have achieved biochemical control using injectable SRLs is expected to hamper the market in the forecast period.
COVID-19 Impact On Somatostatin Receptor Type 2 Market
The COVID-19 pandemic has affected the healthcare systems and has a notable impact on the market. Many patients with neuroendocrine neoplasms (NENs), including phaeochromocytomas, paragangliomas and medullary thyroid carcinoma, may develop Covid-19 in a mild or severe form or be concerned about the influence of viral infection relative to their anti-tumoral therapy.
In general, newly presenting patients should be assessed, and patients recently receiving chemotherapy, targeted therapy or radionuclide therapy, or showing tumor growth, should be closely followed. Some delays in routine follow-up or treatment may not be problematic for previously diagnosed patients with indolent disease. Patients with life-threatening Covid-19-related symptoms should be urgently treated, and long-term anti-tumoral treatments may be temporarily delayed.
Additionally, it is expected that the market for the somatostatin receptor type 2 will undergo impetus growth during the forecast period and continue to witness an excellent growth rate after the end of the pandemic.
Somatostatin Receptor Type 2 Market Segment Analysis
The lanreotide Acetate segment is expected to hold the largest market share in this market segment.
The lanreotide acetate segment held the largest market share in 2020. The segment's growth is attributed to the increasing rare diseases, including pancreatic neuroendocrine tumors, expected to boost the forecast period. For instance, according to the article(Frontiers), on 19 May 2021. Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that somatostatins or synthetic analogs can activate.
Therefore, SSTRs have been widely researched as a diagnostic marker and therapeutic target in pNETs. A large number of studies have demonstrated the clinical significance of SSTRs in pNETs. In this review, relevant literature has been appraised to summarize the most recent empirical evidence addressing the clinical significance of SSTRs in pNETs. Overall, these studies have shown that SSTRs have great value in the diagnosis, treatment, and prognostic prediction of pNETs; however, further research is still necessary.
SSAs function through targeting SSTRs. The most studied SSAs are lanreotide auto gel and octreotide long-acting release (LAR), targeting SSTR5 and SSTR2. The newest SSA, pasireotide, can target a broader scope of SSTRs, including SSTR1, 2, 3, and 5. Thus, due to their anti-secretory effects, SSAs were previously only used to regulate symptoms. However, at present, their anti-proliferative effect has been widely confirmed; from the above statement, the market segment is expected to hold the largest market segment in the forecast period.
Somatostatin Receptor Type 2 Market Geographical Penetration
North America region holds the largest market share in the global somatostatin receptor type 2 market.
North America dominated the market with a revenue share in 2020. The region's growth is benefited due to an increase in patients with neuroendocrine tumors; apoptosis is expected to boost the market in the forecast period. For instance, according to the journal(JCEM), on 16 January 2019. Pulmonary carcinoids (PCs) relate to neuroendocrine tumors that usually overexpress somatostatin receptors (SSTRs). This overexpression produces a molecular basis for tumor imaging and treatment with somatostatin analogs. To evaluate SSTR1 to SSTR5 distribution in a large set of PC tumors and examine whether the expression is associated with clinicopathological and outcome data.
Moreover, they conducted a retrospective study at Helsinki University Hospital and the University of Helsinki. It included 178 PC tumors coupled with patients' clinical data retrieved through Finnish biobanks. Additionally, expression of SSTR1 to SSTR5 was detected in 52%, 75%, 56%, 16%, and 32% of the tumors, respectively. Thus, the North American region has accounted for the largest market share in the forecast period from the above statements.
Somatostatin Receptor Type 2 Companies and Competitive Landscape
The somatostatin receptor type 2 market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc and Zucara Therapeutics Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the somatostatin receptor type 2 market globally.
Somatostatin Receptor Type 2 Market Key Companies to Watch
Crinetics Pharmaceuticals Inc.:
Overview:
Crinetics is a pharmaceutical company that researches, discovers, and develops game-changing therapies for patients with rare endocrine diseases to improve their lives in significant ways.
Product Portfolio:
Crinetics Pharmaceuticals Inc. has continuously set new standards for the continuous manufacturing of PALTUSOTINE (FORMERLY CRN00808).
The global somatostatin receptor type 2 market report would provide access to an approx.38 market data tables, 39 figures and 180 pages.
